BIOTECanada

BIOTECanada is the national non-profit association dedicated to building the bio-based economy in Canada. From cleaner energy to sustainable agriculture; from greener manufacturing to life-saving health therapies, Canadian biotech firms are discovering ways to revolutionize the economy and improve our lives, everyday.

Æterna Zentaris Inc.

Æterna Zentaris Inc. (TSX: AEZ) is a Quebec, Canada-based biopharmaceutical company focused in oncology and endocrine therapy. It has over 250 employees in North America and Europe.

BioMS Medical

BioMS Medical Corp (TSX: MS) is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis. On July 27, 2009 the company announced that its drug, dirucotide, failed to meet its primary endpoint in the Phase III MAESTRO-01 Trial. It will discontinue testing of the drug and the future of the company is unclear.

ConjuChem

ConjuChem Biotechnologies Inc. (TSX: CJB) is a medical biotechnology company located in Montreal, Canada and employs 45 people, 90% of whom are in research and development.

Generex Biotechnology Corporation

Generex Biotechnology Corporation (NasdaqCM: GNBT) is a leader in drug delivery for metabolic diseases through the inner lining of the mouth. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth.

Guardian Biotechnologies

Launched in August 2002, Guardian Biotechnologies Inc. is a privately owned plant biotechnology company that operates from its corporate headquarters in Saskatoon, Saskatchewan, Canada.

InNexus Biotechnology

InNexus Biotechnology, Inc. is a drug company based in British Columbia, Canada. InNexus was founded in 2001 and became a publicly traded corporation in 2003 on the TSX Venture Exchange (TSX: IXS.V). On 2009-12-30, the company filed a Form 15-F with the U.S. Securities and Exchange Commission (SEC) to voluntarily deregister its common stock under the Securities Exchange Act of 1934 and continue its primary listing on the TSX Venture Exchange under the symbol of IXS.V.

IXS is developing what they refer to as DXLA- or DXL-modified antibodies, wherein certain autophilic peptides are integrated with a monoclonal antibody. The DXL-modified antibodies have been shown to have enhanced binding affinity and, as a result, greater potency for use as an improved therapeutic to fight cancer and higher signal strength for use as an improved diagnostic for detecting cancer versus an unmodified antibody.

Iogen Corp.

Iogen Corporation is a Canadian company based in Ottawa, Ontario that was founded by Patrick Foody. Iogen is a company specializing in cellulosic ethanol made from farm waste. They also develop, manufacture, and market enzymes used to modify and improve the processing of natural fibres in the textile, animal feed, and pulp and paper industries.

Medicago

Medicago Inc., Québec City, Canada is a publicly-traded biotechnology company focused on the development, production and commercialization of protein-based biopharmaceuticals (vaccines, monoclonal antibodies, biogenerics etc) by the genetic engineering of plants. Medicago is listed on the TSX Venture Exchange under the symbol "MDG".

Prairie Plant Systems

Prairie Plant Systems is a Saskatoon, Saskatchewan-based company established in 1988. It specializes in biosecure underground growth chambers used for plant-made pharmaceuticals . Its most famous contract was Health Canada's marijuana 2002 award for a cultivation project in Flin Flon, Manitoba.

Resverlogix Corp.

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) focused on developing novel therapies for unmet medical markets, primarily cardiovascular disease (CVD), cancer and fibrotic conditions. Our goal is to improve the quality and longevity of patient’s lives by becoming a leader in the research, development and commercialization of innovative products for these grievous diseases.

SemBioSys Genetics

SemBioSys Genetics Inc. (TSX: SBS) is a biotechnology company that is using its proprietary oilbody/oleosin-based protein production technology to develop high-value proteins including protein-based pharmaceuticals, industrial reagents, food additives, and nutritional oils. The company's strategy is to partner with other companies to enable the commercialization of products that might not otherwise be commercially viable because of high production/manufacturing costs.

Sipco Industries

Sipco Industries Ltd., also known as Sipco Bioengineering Inc., is a Canadian biotechnology company.

Established 1974 in Delta British Columbia, Canada. Sipco has offices in Canada (head office) and the United States, and supplies specialized bio-solutions to government, military & industry customers world-wide.

A world pioneer in enzyme technology, Sipco is best known for helping the United States Postal Service (USPS) with Anthrax following the attacks on the US Senate shortly after September 11, 2001. Sipco supplied a proprietary enzyme technology developed from a product known as Hygrozyme.

YM BioSciences

YM BioSciences Inc. (TSX: YM, AMEX: YMI) is a life sciences product development company based in Mississauga, Ontario, Canada. The Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody™; CYT387, a highly selective JAK 1/2 small molecule inhibitor, CYT997, an orally bioavailable, potent, vascular disrupting agent (VDA) and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl.